Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Jean-Louis Montastruc19
Antiparkinson Agents (adverse effects)43
Jean-Louis Montastruc Sauf Antiparkinson Agents (adverse effects)" 14
Antiparkinson Agents (adverse effects) Sauf Jean-Louis Montastruc" 38
Jean-Louis Montastruc Et Antiparkinson Agents (adverse effects) 5
Jean-Louis Montastruc Ou Antiparkinson Agents (adverse effects) 57
Corpus679
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 5.
Ident.Authors (with country if any)Title
000151 Julia Grossac [France] ; Stéphanie Ruiz [France] ; Emmanuelle Bondon-Guitton [France] ; Franck-Emmanuel Roux [France] ; Olivier Fourcade [France] ; Jean-Louis Montastruc [France] ; Thomas Geeraerts [France]Severe intracranial bleeding related to vitamin K Antagonist‐Ropinirole interaction
000208 Jean-Louis Montastruc [France] ; Anne Charlotte Danton [France] ; Genevieve Durrieu [France] ; Isabelle Lacroix [France] ; Pascale Olivier [France] ; Agnés Sommet [France] ; Jean-Michel Senard [France]Neuropathy as a potential complication of levodopa use in Parkinson's disease: A Pharmacological and Pharmacovigilance point of view
000312 Adeline Gallini [France] ; Agnès Sommet [France] ; Anne-Marie Salandini [France] ; Patrick Veyssière [France] ; Jean-Louis Montastruc [France] ; Jean-Louis Montastruc [France]Weight‐loss associated with anti‐dementia drugs in a patient with Parkinson's disease
000506 Jean-Louis Montastruc [France] ; Olivier Rascol [France]Modafinil and pramipexole‐associated somnolence
000518 Jean-Louis Montastruc [France]Treatment of Parkinson's disease should begin with a dopamine agonist

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024